Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2024-09-30 Regulatory Filings
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Change of Company Auditor 1 page 94.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement titled 'CHANGE OF COMPANY AUDITOR' dated 1 October 2024. It announces the appointment of a new auditor, William Buck Audit (Vic) Pty Ltd, replacing Ernst & Young. It mentions that the appointment has been approved by the Australian Securities & Investment Commission and that a resolution will be tabled at the upcoming Annual General Meeting to confirm the appointment. The document is short (2371 characters) and serves as an announcement of a change in auditor rather than a full audit report or financial statements. It does not contain audit results or applied accounting principles, so it is not an Audit Report (AR). It is also not a full Annual Report (10-K) or any other financial report. The content fits best with a Regulatory Filing (RNS) as it is a regulatory announcement about auditor change, which does not fit other more specific categories.
2024-09-30 English
Completion of avicursen (ATL1102) toxicology study 2 pages 268.8KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the successful completion of a nine-month non-human primate toxicology study for the company's lead drug candidate, avicursen. It discusses the study's results, regulatory implications, and next steps including planned discussions with the FDA. The document does not contain detailed financial data, comprehensive financial statements, or full regulatory filings. It is an update on a clinical development milestone and regulatory progress rather than a formal report or filing. The document is relatively short (4591 characters) and reads like a corporate announcement. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and updates that do not fit other specific categories.
2024-09-29 English
Percheron Therapeutics Limited Corporate Presentation 26 pages 1.9MB
Investor Presentation Classification · 95% confidence The document is titled 'PERCHERON THERAPEUTICS CORPORATE PRESENTATION' and is described as an updated nonconfidential corporate presentation for shareholders and investors. It includes detailed information about the company's pipeline, financial position, clinical trials, and upcoming milestones. The text mentions that the presentation is intended for investor discussions and shareholder meetings. There is no indication that this is a full annual or interim report, audit report, or earnings release. Instead, it is a detailed presentation aimed at investors, covering strategy, financials, and market position. Therefore, the document fits the definition of an Investor Presentation (IP). The document length is substantial (15,000 characters), supporting that it is a full presentation rather than a brief announcement or regulatory filing.
2024-09-03 English
ATL1102 Shows Preclinical Activity in Autoimmune Epilepsy 3 pages 157.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Percheron Therapeutics Limited dated 3 September 2024. It reports new preclinical data for their drug avicursen (ATL1102) in a mouse model of autoimmune epilepsy. The content focuses on scientific study results, experimental design, and next steps for the drug development. There are no financial statements, no regulatory certifications, no voting results, no management changes, no earnings data, and no investor presentation format. The document is a corporate announcement of scientific data and progress, typical of a Capital/Financing Update or general company update. However, since it is primarily about new preclinical data and drug development progress without direct financing or capital structure changes, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories. The document is longer than 5,000 characters and contains substantive content, so it is not a mere report publication announcement. Therefore, the best classification is Regulatory Filings (RNS).
2024-09-02 English
Appendix 4E and Annual Report 61 pages 5.5MB
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT FY24' and covers the full fiscal year ended 30 June 2024. It includes detailed financial results, a letter from the Chair, CEO report, financial statements, auditor's report, corporate governance, and other comprehensive information typical of a full annual report. The presence of audited accounts and an independent auditor's report further confirms this is a full annual report document. The length of the document (15,000 characters) and the detailed content indicate it is not merely an announcement or summary but the full report itself. Therefore, the appropriate classification is Annual Report (10-K). FY 2024
2024-08-28 English
Appendix 4G and Corporate Governance Statement 28 pages 723.6KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G' and references the ASX Listing Rules, specifically Listing Rule 4.10.3 and 4.7.4, which relate to corporate governance disclosures. It includes a key to disclosures against the ASX Corporate Governance Council Principles and Recommendations. The document states that the corporate governance statement is available on the company's website and that Appendix 4G is lodged with ASX alongside the annual report. The content is focused on governance disclosures and compliance with ASX listing rules rather than financial results or management changes. Appendix 4G is a regulatory filing required by ASX to confirm governance disclosures and is not the annual report itself or a governance report but a compliance form. The document length is 15,000 characters, indicating it is a full filing, not a brief announcement. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance filings that do not fit other categories.
2024-08-28 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.